JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2020, 69(1):3-16 | DOI: 10.36290/csf.2020.001

Metal complexes in medicine and pharmacy - the past and the present II

Ladislav Habala*, Jindra Valentová
Katedra chemickej teórie liečiv, Farmaceutická fakulta UK, Bratislava, SR

Therapy of malignant tumors is among the oldest and at the same time the most promising application areas of therapeutic metal complexes. The second part of our survey on metallopharmaceuticals deals with historical development and current state of coordination compounds in cancer therapy. It starts with the most famous and most successful metallodrug - cisplatin. After a brief account of the discovery of the anticancer properties of this substance follows the discussion of its chemical properties, toxicity, clinical application and resistance. Hereafter, complexes of other metals along with innovative research directions are addressed. The aim of this brief survey is to provide basic overview of the area of metallopharmacy, aimed at specialists in pharmacy and chemistry as well as at the general educated public.

Keywords: bioinorganic chemistry; metallopharmaceuticals; metal complexes; Chemotherapy; platinum; ruthenium
Grants and funding:

Práca bola podporovaná Vedeckou grantovou agentúrou MŠVVaŠ SR a SAV, grant VEGA 1/0346/16.

Received: November 15, 2019; Accepted: December 10, 2019; Published: January 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Habala L, Valentová J. Metal complexes in medicine and pharmacy - the past and the present II. Čes. slov. farm. 2020;69(1):3-16. doi: 10.36290/csf.2020.001.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Habala L., Valentová J. Komplexy kovov v medicíne a farmácii - minulosť a súčasnosť I. Čes. slov. Farm. 2018; 67, 182-191. Go to original source...
    2. DeVita V. T., Chu E. A history of cancer chemotherapy. Cancer Res. 2008; 68, 8643-8653. Go to original source... Go to PubMed...
    3. Papac R. J. Origins of cancer therapy. Yale J. Biol. Med. 2001; 74, 391-398.
    4. Hajdu S. I. 2000 years of chemotherapy of tumors. Cancer 2005; 103, 1097-1102. Go to original source... Go to PubMed...
    5. Morrison W. B. Cancer chemotherapy: An annotated history. J. Vet. Intern. Med. 2010; 24, 1249-1262. Go to original source... Go to PubMed...
    6. Gilman A. The initial clinical trial of nitrogen mustard. Am. J. Surg. 1963; 105, 574-578. Go to original source... Go to PubMed...
    7. Humphrey R. W., Brockway-Lunardi L. M., Bonk D. T., Dohoney K. M., Doroshow J. H., Meech S. J., Ratain M. J., Topalian S. L., Pardoll D. M. Opportunities and challenges in the development of experimental drug combinations for cancer. J. Natl. Cancer Inst. 2011; 103, 1222-1226. Go to original source... Go to PubMed...
    8. Oktábec Z., Jampílek J. Stručná historie chemoterapie. Chem. Listy 2013; 107, 151-159.
    9. Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg. Chem. 2019; 88, 102925. Go to original source... Go to PubMed...
    10. Lippert B. Cisplatin: Chemistry and biochemistry of a leading anticancer drug. Zürich: Verlag Helvetica Chimica Acta 1999. Go to original source...
    11. Peyron M. Ueber die Einwirkung des Ammoniaks auf Platinchlorür. Ann. Chem. Pharm. 1844; 51, 1-29. Go to original source...
    12. Barry N. P. E., Sadler P. J. 100 years of metal coordination chemistry: from Alfred Werner to anticancer metallodrugs. Pure Appl. Chem. 2014; 86, 1897-1910. Go to original source...
    13. Muggia F. M., Bonetti A., Hoeschele J. D., Rozencweig M., Howell S. B. Platinum antitumor complexes: 50 years since Barnett Rosenberg's discovery. J. Clin. Oncol. 2015; 33, 4219-4226. Go to original source... Go to PubMed...
    14. Grimley E. Discovery and identification of the first platinum anticancer compound. Inorg. Chim. Acta 2019; 495, 118986. Go to original source...
    15. Wilson J. J., Lippard S. J. Synthetic methods for the preparation of platinum anticancer complexes. Chem. Rev. 2014; 114, 4470-4495. Go to original source... Go to PubMed...
    16. Motzer R. J. Optimal treatment for advanced seminoma? Cancer 1993; 72, 3-4. Go to original source...
    17. Marloye M., Berger G., Gelbcke M., Dufrasne F. A survey of the mechanisms of action of anticancer transition metal complexes. Future Med. Chem. 2016; 8, 2263-2286. Go to original source... Go to PubMed...
    18. Wexselblatt E., Yavin E., Gibson D. Cellular interactions of platinum drugs. Inorg. Chim. Acta 2012; 393, 75-83. Go to original source...
    19. Arnesano F., Losacco M., Natile G. An updated view of cisplatin transport. Eur. J. Inorg. Chem. 2013; 2013, 2701-2711. Go to original source...
    20. Arnesano F., Nardella M. I., Natile G. Platinum drugs, copper transporters and copper chelators. Coord. Chem. Rev. 2018; 374, 254-260. Go to original source...
    21. Yu J. J. Unlocking the molecular mechanisms of DNA repair and platinum drug resistance in cancer chemotherapy. Curr. Drug Ther. 2009; 4, 19-28. Go to original source...
    22. Bergamo A., Dyson P. J., Sava G. The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions. Coord. Chem. Rev. 2018; 360, 17-33. Go to original source...
    23. Wang X., Guo Z. The role of sulfur in platinum anticancer chemotherapy. Anti-Cancer Agents Med. Chem. 2007; 7, 19-34. Go to original source... Go to PubMed...
    24. Galluzzi L., Senovilla L., Vitale I., Michels J., Martins I., Kepp O., Castedo M., Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31, 1869-1883. Go to original source... Go to PubMed...
    25. Florea A.-M., Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 2011; 3, 1351-1371. Go to original source... Go to PubMed...
    26. Dilruba S., Kalayda G. V. Platinum-based drugs: past, present and future. Cancer Chemother. Pharmacol. 2016; 77, 1103-1124. Go to original source... Go to PubMed...
    27. Di Pasqua A. J., Goodisman J., Dabrowiak J. C. Understanding how the platinum anticancer drug carboplatin works: From the bottle to the cell. Inorg. Chim. Acta 2012; 389, 29-35. Go to original source...
    28. Alcindor T., Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr. Oncol. 2011; 18, 18-25. Go to original source... Go to PubMed...
    29. Cai L., Yu C., Ba L., Liu Q., Qian Y., Yang B., Gao C. Anticancer platinum-based complexes with non-classical structures. Appl. Organomet. Chem. 2018; 32, e4228. Go to original source...
    30. Montaña Á. M., Batalla C. The rational design of anticancer platinum complexes: the importance of the structure-activity relationship. Curr. Med. Chem. 2009; 16, 2235-2260. Go to original source... Go to PubMed...
    31. Coluccia M., Natile G. Trans-platinum complexes in cancer therapy. Anti-Cancer Agents Med. Chem. 2007; 7, 111-123. Go to original source... Go to PubMed...
    32. Wheate N. J., Collins J. G. Multi-nuclear platinum drugs: a new paradigm in chemotherapy. Curr. Med. Chem. Anti-Cancer Agents 2005; 5, 267-279. Go to original source... Go to PubMed...
    33. Ravera M., Gabano E., McGlinchey M. J., Osella D. A view on multi-action Pt(IV) antitumor prodrugs. Inorg. Chim. Acta 2009; 492, 32-47. Go to original source...
    34. Gibson D. Multi-action Pt(IV) anticancer agents; do we understand how they work? J. Inorg. Biochem. 2019; 191, 77-84. Go to original source... Go to PubMed...
    35. Medici S., Peana M., Nurchi V. M., Lachowicz J. I., Crisponi G., Zoroddu M. A. Noble metals in medicine: Latest advances. Coord. Chem. Rev. 2015; 284, 329-350. Go to original source...
    36. Simpson P. V., Desai N. M., Casari I., Massi M., Falasca M. Metal-based antitumor compounds: beyond cisplatin. Future Med. Chem. 2019; 11, 119-135. Go to original source... Go to PubMed...
    37. Trudu F., Amato F., Vaňhara P., Pivetta P., Peña-Méndez E. M., Havel J. Coordination compounds in cancer: past, present and perspectives. Future Med. Chem. J. Appl. Biomed. 2015; 13, 79-103. Go to original source...
    38. Kostova I. Ruthenium complexes as anticancer agents. Curr. Med. Chem. 2006; 13, 1085-1107. Go to original source... Go to PubMed...
    39. Bergamo A., Gaiddon C., Schellens J. H. M., Beijnen J. H., Sava G. Approaching tumour therapy beyond platinum drugs. Status of the art and perspectives of ruthenium drug candidates. J. Inorg. Biochem. 2012; 106, 90-99. Go to original source... Go to PubMed...
    40. Coverdale J. P. C., Laroiya-McCarron T., Romero-Canelón I. Designing ruthenium anticancer drugs: what have we learnt from the key drug candidates? Inorganics 2019; 7, 31. Go to original source...
    41. Alessio E., Messori L. NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: a case story in medicinal inorganic chemistry. Molecules 2019; 24, 1995. Go to original source... Go to PubMed...
    42. Brabec V., Kasparkova J. Ruthenium coordination compounds of biological and biomedical significance. DNA binding agents. Coord. Chem. Rev. 2018; 376, 75-94. Go to original source...
    43. Graf N., Lippard S. J. Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv. Drug Deliv. Rev. 2012; 64, 993-1004. Go to original source... Go to PubMed...
    44. Thota S., Rodrigues D. A., Crans D. C., Barreiro E. J. Ru(II) compounds: next-generation anticancer metallotherapeutics? J. Med. Chem. 2018; 61, 5805-5821. Go to original source... Go to PubMed...
    45. Garoufis A., Hadjikakou S. K., Hadjiliadis N. Palladium coordination compounds as anti-viral, anti-fungal, anti-microbial and anti-tumor agents. Coord. Chem. Rev. 2009; 253, 1384-1397. Go to original source...
    46. Fischer-Fodor E., Mikláš R., Rišiaňová L., Cenariu M., Grosu I. G., Virag P., Perde-Schrepler M., Tomuleasa C., Berindan-Neagoe I., Devínsky F., Miklášová N. Novel palladium(II) complexes that influence prominin-1/CD133 expression and stem cell factor release in tumor cells. Molecules 2017; 22, 561. Go to original source... Go to PubMed...
    47. Alam M. N., Huq F. Comprehensive review on tumour active palladium compounds and structure-activity relationships. Coord. Chem. Rev. 2016; 316, 36-67. Go to original source...
    48. Kostova I. Titanium and vanadium complexes as anticancer agents. Anti-Cancer Agents Med. Chem. 2009; 9, 827-842. Go to original source... Go to PubMed...
    49. Bowman D. C. The amazingly versatile titanocene derivatives. J. Chem. Ed. 2006; 83, 735-740. Go to original source...
    50. Skoupilová H., Hrstka R. Pokroky ve využití organokovových sloučenin při vývoji protinádorových léčiv. Klin. Onkol. 2019; 32(Suppl 3), 3S25-3S33. Go to original source...
    51. Buettner K. M., Valentine A. M. Bioinorganic chemistry of titanium. Chem. Rev. 2012; 112, 1863-1881. Go to original source... Go to PubMed...
    52. Olszewski U., Hamilton G. Mechanisms of cytotoxicity of anticancer titanocenes. Anti-Cancer Agents Med. Chem. 2010; 10, 302-311. Go to original source... Go to PubMed...
    53. Tshuva E. Y., Ashenhurst J. A. Cytotoxic titanium(IV) complexes: renaissance. Eur. J. Inorg. Chem. 2009; 2009, 2203-2218. Go to original source...
    54. Jakupec, M. A., Keppler B. K. Gallium in cancer treatment. Curr. Top. Med. Chem. 2004; 4, 1575-1583. Go to original source... Go to PubMed...
    55. Lessa J. A., Parrilha G. L., Beraldo H. Gallium complexes as new promising metallodrug candidates. Inorg. Chim. Acta 2012; 393, 53-63. Go to original source...
    56. Timerbaev A. R. Advances in developing tris(8-quinolinolato)gallium(III) as an anticancer drug: critical appraisal and prospects. Metallomics 2009; 1, 193-198. Go to original source... Go to PubMed...
    57. Devi J., Yadav J. Recent advancements in organotin(IV) complexes as potential anticancer agents. Anti-Cancer Agents Med. Chem. 2018; 18, 335-353. Go to original source... Go to PubMed...
    58. Niu L., Li Y., Li Q. Medicinal properties of organotin compounds and their limitations caused by toxicity. Inorg. Chim. Acta 2014; 423, 2-13. Go to original source...
    59. Ott I. On the medicinal chemistry of gold complexes as anticancer drugs. Coord. Chem. Rev. 2009; 253, 1670-1681. Go to original source...
    60. Onodera T., Momose I., Kawada M. Potential anticancer activity of auranofin. Chem. Pharm. Bull. 2019; 67, 186-191. Go to original source... Go to PubMed...
    61. Hoonjan M., Jadhav V., Bhatt P. Arsenic trioxide: insights into its evolution to an anticancer agent. J. Biol. Inorg. Chem. 2018; 23, 313-329. Go to original source... Go to PubMed...
    62. Dilda P. J., Hogg P. J. Arsenical-based cancer drugs. Cancer Treat. Rev. 2007; 33, 542-564. Go to original source... Go to PubMed...
    63. Bishayee A., Waghray A., Patel M. A., Chatterjee M. Vanadium in the detection, prevention and treatment of cancer: the in vivo evidence. Cancer Lett. 2010; 294, 1-12. Go to original source... Go to PubMed...
    64. Pessoa J. C., Etcheverry S., Gambino D. Vanadium compounds in medicine. Coord. Chem. Rev. 2015; 301-302, 24-48. Go to original source... Go to PubMed...
    65. Habala L., Bartel C., Giester G., Jakupec M. A., Keppler B. K., Rompel A. Complexes of N-hydroxyethyl-N-benzimidazolylmethylethylenediaminediacetic acid with group 12 metals and vanadium - synthesis, structure and bioactivity of the vanadium complex. J. Inorg. Biochem. 2015; 147, 147-152. Go to original source... Go to PubMed...
    66. D'Cruz O. J., Uckun F. M. Metvan: a novel oxovanadium(IV) complex with broad spectrum anticancer activity. Expert Opin. Investig. Drugs 2002; 11, 1829-1836. Go to original source... Go to PubMed...
    67. Sutton E. C., McDevitt C. E., Yglesias M. V., Cunningham R. M., DeRose V. J. Tracking the cellular targets of platinum anticancer drugs: current tools and emergent methods. Inorg. Chim. Acta 2019; 498, 118984. Go to original source...
    68. Deo K. M., Pages B. J., Ang D. L., Gordon C. P., Aldrich-Wright J. R. Transition metal intercalators as anticancer agents - recent advances. Int. J. Mol. Sci. 2016; 17, 1818. Go to original source... Go to PubMed...
    69. Ma D.-L., Wu C., Cheng S.-S., Lee F.-W., Han Q.-B., Leung C.-H. Development of natural product-conjugated metal complexes as cancer therapies. Int. J. Mol. Sci. 2019; 20, 341. Go to original source... Go to PubMed...
    70. Wang X., Wang X., Jin S., Muhammad N., Guo Z. Stimuli-responsive therapeutic metallodrugs. Chem. Rev. 2019; 119, 1138-1192. Go to original source... Go to PubMed...
    71. Meggers E. Targeting proteins with metal complexes. Chem. Commun. 2009; 1001-1010. Go to original source... Go to PubMed...
    72. Poursharifi M., Wlodarczyk M. T., Mieszawska A. J. Nano-based systems and biomacromolecules as carriers for metallodrugs in anticancer therapy. Inorganics 2019; 7, 2. Go to original source...
    73. Imberti C., Zhang P., Huang H., Sadler P. J. New designs for phototherapeutic transition metal complexes. Angew. Chem. Int. Ed. 2019; 58, 2-15.
    74. Munro S., Colón K. L., Yin H., Roque J., Konda P., Gujar S., Thummel R. P., Lilge L., Cameron C. G., McFarland S. A. Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities, and highlights from the development of TLD1433. Chem. Rev. 2019; 119, 797-828. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.